Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2008-005462-32-FR
EUCTR2008-005462-32-FRActive, not recruitingNot Applicable

Effet de la rhDNase sur la biodistribution des protéases du neutrophile dans les expectorations des patients atteints de mucoviscidose - BioDNase

CHRU de TOURS0 sitesStarted: October 21, 2008Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •- Homme ou femme de plus de 18 ans
  • •- Atteint(e) de mucoviscidose
  • •- Recevant un traitement au long cours de rhDNase selon l’indication AMM de la molécule
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range
  • •F.1.3 Elderly (>=65 years) no
  • •F.1.3.1 Number of subjects for this age range

Exclusion Criteria

  • •- Poussée aiguë de l'atteinte broncho-pulmonaire ou hospitalisation pour traitement de la maladie au cours des 2 semaines précédentes
  • •- Exposition à une antibiothérapie ou traitement par corticoïdes (quelle que soit la voie d’administration) au cours des 2 semaines précédentes
  • •- Colonisé(e) par Burkholderia cepacia ou Stenotrophomonas maltophilia

Investigators

Similar Trials

Completed
Not Applicable
Peripheral targeting of inhaled rhDNase in stable CF patients.Cystic Fibrosis (CF)10038716
NL-OMON33580Erasmus MC, Universitair Medisch Centrum Rotterdam25
Completed
Phase 4
RhDNase and Biodistribution of PMN Serine Proteases in Cystic Fibrosis SputumCystic Fibrosis
NCT00843817University Hospital, Tours15
Active, not recruiting
Not Applicable
‘Peripheral targeting of inhaled rhDNase in stable CF patients.’MedDRA version: 9.1Level: LLTClassification code 10011762Term: Cystic fibrosisMedDRA version: 9.1Level: LLTClassification code 10011763Term: Cystic fibrosis lungCystic Fibrosis
EUCTR2007-000935-25-NLErasmusMC - Sophia Children's Hospital50
Active, not recruiting
Not Applicable
Concentraciones plasmáticas e intracelulares de Raltegravir y Etravirina administrados una vez al día (800 mg y 400 mg, respectivamente) comparado con su dosificación estándard (400 mg y 200 mg/12 h) en pacientes con infección por el VIH.(Plasma and intracellular levels of once daily Raltegravir and Etravirine (800 mg and 400 mg, respectively) compared with their usual dosage (400 mg y 200 mg/12 h) in HIV-infected patients). - RAET-QDPacientes con infección por el VIH en tratamiento con raltegravir o etravirina.HIV-Patients on treatment with raltegravir or etravirine
EUCTR2009-014480-39-ESuis Fernando López Cortés16
Completed
Not Applicable
Investigating the tissue migration of anti-MRSA drugs in soft tissue infectionsPressure ulcer in sacral and ischial region which have been performed flap reconstruction.
JPRN-UMIN000036933Saitama Medical University Hospital60